Can-Fite: Pre-Clinical Data Positions Namodenoson as an anti-Obesity Agent
January 08 2019 - 8:00AM
Business Wire
- Company filed patent application for
the utilization of Namodenoson as an anti-obesity drug
- A Phase II study of Namodenoson is
enrolling patients for the treatment of NAFLD/NASH
- Data from Phase II study of
Namodenoson in advanced liver cancer expected to be released in
Q1/19
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a
biotechnology company advancing a pipeline of proprietary small
molecule drugs that address cancer, liver and inflammatory
diseases, today announced new pre-clinical findings demonstrating
that Namodenoson, inhibits lipid production and fat accumulation in
adipocytes (lipid producing cells).
These findings together with the excellent safety profile of
Namodenoson support its potential utilization as an anti-obesity
drug.
New pre-clinical studies of Namodenoson showed a significant
decrease in lipid production and fat accumulation utilizing 3T3-L1
adipocytes, functioning as lipid producing cells and are also
responsible for fat storage. Namodenoson was also shown to inhibit
the proliferation of adipocytes, further hampering the expansion of
fat producing cells. A patent application for the utilization of
Namodenoson as an anti-obesity drug has been filed.
“These new preclinical data, in tandem with the safety profile
of Namodenoson in humans demonstrated to date, serve as robust
support for its potential development as an anti-obesity drug,”
said Pnina Fishman, Ph.D., CEO of Can-Fite BioPharma. “This
complements Namodenoson’s potential positive effects on steatosis,
inflammation and fibrosis, as evidenced in preclinical studies in
non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
(NAFLD/NASH). These additional data regarding the inhibition of fat
accumulation also serve as encouragement for our Phase II
NAFLD/NASH study where we hope to reproduce these findings.”
The global obesity treatment market is lucrative due to the
awareness of a link between chronic diseases and obesity and
according to Market Research Future is expected to reach USD 12
billion by 2023.
Can Fite is currently enrolling patients for a Phase II study of
Namodenoson in NAFLD/NASH patients with evidence of active
inflammation. The primary study end point is serum ALT levels, and
secondary end point is percentage of liver fat, as measured by PDFF
(proton density fat fraction).
In addition, the Company expects to release data from its Phase
II advanced liver cancer study of Namodenoson during Q1/19.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with
high affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson is being evaluated in Phase II trials for two
indications, as a second line treatment for hepatocellular
carcinoma, and as a treatment for non-alcoholic fatty liver disease
(NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly
expressed in diseased cells whereas low expression is found in
normal cells. This differential effect accounts for the excellent
safety profile of the drug.
About Can-Fite BioPharma
Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets
in the treatment of cancer, inflammatory disease and sexual
dysfunction. The Company's lead drug candidate, Piclidenoson, is
currently in a Phase III trial for rheumatoid arthritis and
psoriasis. Can-Fite's liver cancer drug, Namodenoson, is in Phase
II trials for hepatocellular carcinoma (HCC), the most common form
of liver cancer, and for the treatment of non-alcoholic
steatohepatitis (NASH). Namodenoson has been granted Orphan Drug
Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for HCC by the U.S. Food and Drug
Administration. Namodenoson has also shown proof of concept to
potentially treat other cancers including colon, prostate, and
melanoma. CF602, the Company's third drug candidate, has shown
efficacy in the treatment of erectile dysfunction in preclinical
studies and the Company is investigating additional compounds,
targeting A3AR, for the treatment of sexual dysfunction. These
drugs have an excellent safety profile with experience in over
1,000 patients in clinical studies to date. For more information
please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite's expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product
development efforts, business, financial condition, results of
operations, strategies or prospects. In addition, from time to
time, Can-Fite or its representatives have made or may make
forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe," "expect," "intend," "plan," "may," "should" or
"anticipate" or their negatives or other variations of these words
or other comparable words or by the fact that these statements do
not relate strictly to historical or current matters. These
forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or
with the approval of one of Can-Fite's authorized executive
officers. Forward-looking statements relate to anticipated or
expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to
risks and uncertainties that could cause Can-Fite's actual results
to differ materially from any future results expressed or implied
by the forward-looking statements. Many factors could cause
Can-Fite's actual activities or results to differ materially from
the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ
materially from those expressed or implied in such forward-looking
statements include, but are not limited to: the initiation, timing,
progress and results of our preclinical studies, clinical trials
and other product candidate development efforts; our ability to
advance our product candidates into clinical trials or to
successfully complete our preclinical studies or clinical trials;
our receipt of regulatory approvals for our product candidates, and
the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain corporate
collaborations; the implementation of our business model and
strategic plans for our business and product candidates; the scope
of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
our ability to operate our business without infringing the
intellectual property rights of others; estimates of our expenses,
future revenues, capital requirements and our needs for additional
financing; competitive companies, technologies and our industry;
statements as to the impact of the political and security situation
in Israel on our business; and risks and other risk factors
detailed in Can-Fite's filings with the SEC and in its periodic
filings with the TASE. In addition, Can-Fite operates in an
industry sector where securities values are highly volatile and may
be influenced by economic and other factors beyond its control.
Can-Fite does not undertake any obligation to publicly update these
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190108005562/en/
Motti Farbsteininfo@canfite.com+972-3-9241114
Media ContactDGI CommLaura Radocajlradocaj@dgicomm.com
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Mar 2024 to Apr 2024
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2023 to Apr 2024